BioGaia AB (publ) (FRA:BGLA)

Market Cap	983.85M +0.7%
Revenue (ttm)	142.75M +9.8%
Net Income	31.36M +21.1%
EPS	0.31 +21.3%
Shares Out	n/a
PE Ratio	31.37
Forward PE	25.85
Dividend	0.37 (3.85%)
Ex-Dividend Date	May 8, 2026

Volume	n/a
Open	9.55
Previous Close	9.49
Day's Range	9.55 - 9.55
52-Week Range	8.76 - 12.32
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 12, 2027

About BioGaia AB

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablet...

• Industry: Pharmaceutical Preparations
• Founded: 1990
• Employees: 251
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BGLA

Financial Performance

In 2025, BioGaia AB's revenue was 1.54 billion, an increase of 8.11% compared to the previous year's 1.42 billion. Earnings were 332.76 million, a decrease of -5.30%.

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 19, 2026

Data Sources Report a data error